Hjem › Vaso-okklusive kriser › Georgia
Vaso-okklusive kriser kliniske forsøg i Georgia
4 studier for Vaso-okklusive kriser søger deltagere på steder i Georgia.
Byer i Georgia
Officiel studietekst (engelsk)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Augusta University Georgia, Augusta
- WCG Sonar Clinical Research, Riverdale
RekruttererFase 3
Alder 12 til 100 · Alle køn · Opdateret 28. sep. 2026 · NCT06439082Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Arthur M. Blank Hospital-Children's Healthcare of Atlanta, Atlanta
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Arthur M. Blank Hospital- Children's Healthcare of Atlanta, Atlanta
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT07224360Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Augusta University Georgia, Augusta
RekruttererFase 4
6 Months – 100 Years · Alle køn · Opdateret 8. jun. 2026 · NCT04657822Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.